Literature DB >> 21796732

Ancient origin of a deletion in human BST2/Tetherin that confers protection against viral zoonoses.

Daniel Sauter1, Michael Vogl, Frank Kirchhoff.   

Abstract

Bone marrow stromal antigen 2 (BST2)/Tetherin is an antiviral factor that blocks the release of enveloped virions from infected cells. Recent data suggest that efficient BST2 antagonism was a prerequisite for the global spread of HIV/AIDS. Most simian immunodeficiency viruses (SIVs), including the direct precursors of HIV, use their Nef protein to antagonize BST2 of their respective host species. Human BST2, however, contains a five amino acid deletion in its cytoplasmic domain that confers resistance to Nef. Thus, this antiviral factor constitutes a major barrier to effective zoonotic transmissions of SIVs to humans. Here, we show that this protective deletion has already been present in Neanderthal and Denisovan BST2 and thus evolved at least 800,000 years ago. This ancient origin helps to explain why effectively spreading zoonotic transmissions of SIVs to humans have been rare, although SIVs are widespread in African nonhuman primates and humans must have been exposed to these viruses many times.
© 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21796732     DOI: 10.1002/humu.21571

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  17 in total

Review 1.  HIV-1 Vpu - an ion channel in search of a job.

Authors:  Klaus Strebel
Journal:  Biochim Biophys Acta       Date:  2013-07-03

2.  Efficient Vpu-Mediated Tetherin Antagonism by an HIV-1 Group O Strain.

Authors:  Katharina Mack; Kathrin Starz; Daniel Sauter; Simon Langer; Frederic Bibollet-Ruche; Gerald H Learn; Christina M Stürzel; Marie Leoz; Jean-Christophe Plantier; Matthias Geyer; Beatrice H Hahn; Frank Kirchhoff
Journal:  J Virol       Date:  2017-02-28       Impact factor: 5.103

3.  Preadaptation of Simian Immunodeficiency Virus SIVsmm Facilitated Env-Mediated Counteraction of Human Tetherin by Human Immunodeficiency Virus Type 2.

Authors:  Elena Heusinger; Katja Deppe; Paola Sette; Christian Krapp; Dorota Kmiec; Silvia F Kluge; Preston A Marx; Cristian Apetrei; Frank Kirchhoff; Daniel Sauter
Journal:  J Virol       Date:  2018-08-29       Impact factor: 5.103

4.  Functional antagonism of rhesus macaque and chimpanzee BST-2 by HIV-1 Vpu is mediated by cytoplasmic domain interactions.

Authors:  Takeshi Yoshida; Yoshio Koyanagi; Klaus Strebel
Journal:  J Virol       Date:  2013-10-09       Impact factor: 5.103

Review 5.  Host gene evolution traces the evolutionary history of ancient primate lentiviruses.

Authors:  Alex A Compton; Harmit S Malik; Michael Emerman
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-08-12       Impact factor: 6.237

6.  Understanding restriction factors and intrinsic immunity: insights and lessons from the primate lentiviruses.

Authors:  Andrea Kirmaier; Annabel Krupp; Welkin E Johnson
Journal:  Future Virol       Date:  2014       Impact factor: 1.831

7.  Vpu and BST2: Still Not There Yet?

Authors:  Kei Sato; Peter Gee; Yoshio Koyanagi
Journal:  Front Microbiol       Date:  2012-04-09       Impact factor: 5.640

8.  Counteraction of tetherin antiviral activity by two closely related SIVs differing by the presence of a Vpu gene.

Authors:  Kristina Nikovics; Marie-Christine Dazza; Michel Ekwalanga; Fabrizio Mammano; François Clavel; Sentob Saragosti
Journal:  PLoS One       Date:  2012-04-17       Impact factor: 3.240

9.  Simian Immunodeficiency Virus SIVgsn-99CM71 Vpu Employs Different Amino Acids To Antagonize Human and Greater Spot-Nosed Monkey BST-2.

Authors:  Weitong Yao; Klaus Strebel; Shoji Yamaoka; Takeshi Yoshida
Journal:  J Virol       Date:  2021-12-08       Impact factor: 6.549

10.  Differential sensitivities of tetherin isoforms to counteraction by primate lentiviruses.

Authors:  Julia Weinelt; Stuart J D Neil
Journal:  J Virol       Date:  2014-03-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.